B12 Injections for Documented Deficiency
For adults with documented B12 deficiency WITHOUT neurological involvement, administer hydroxocobalamin 1 mg intramuscularly three times per week for 2 weeks, followed by lifelong maintenance of 1 mg intramuscularly every 2-3 months 1.
Initial Treatment Algorithm
Step 1: Assess for Neurological Involvement
Before initiating treatment, evaluate for neurological symptoms including:
- Unexplained sensory disturbances
- Motor dysfunction
- Gait abnormalities
- Cognitive impairment
Critical caveat: If ANY neurological symptoms are present, seek urgent specialist advice from neurology and hematology, as the treatment regimen differs significantly 1.
Step 2: Treatment Based on Neurological Status
WITHOUT Neurological Involvement (Standard Regimen):
- Loading phase: Hydroxocobalamin 1 mg IM three times weekly for 2 weeks (total of 6 injections)
- Maintenance phase: Hydroxocobalamin 1 mg IM every 2-3 months for life 1
WITH Neurological Involvement (Intensive Regimen):
- Loading phase: Hydroxocobalamin 1 mg IM on alternate days until no further clinical improvement
- Maintenance phase: Hydroxocobalamin 1 mg IM every 2 months 1
Critical Safety Considerations
Never administer folic acid before treating B12 deficiency - this can mask the underlying B12 deficiency while allowing irreversible subacute combined degeneration of the spinal cord to progress 1, 2. This is a potentially catastrophic error that must be avoided.
Practical Dosing Details
The standard formulation is cyanocobalamin 1000 mcg/mL (1 mg/mL) for intramuscular or subcutaneous use 2. While the guidelines reference hydroxocobalamin, cyanocobalamin is the FDA-approved formulation available in the United States and is clinically equivalent for most patients 2.
Common Pitfalls to Avoid
Insufficient loading dose: A 2016 study demonstrated that shorter injection regimens (3 injections) are inadequate to treat B12 deficiency biochemically, with only the 6-injection regimen successfully reversing all deficiencies 3. Do not abbreviate the loading phase.
Premature discontinuation: Patients with pernicious anemia or malabsorption require lifelong monthly injections. Failure to continue maintenance therapy will result in recurrence of anemia and irreversible neurological damage 2.
One-size-fits-all maintenance: While guidelines recommend every 2-3 months, clinical experience suggests up to 50% of patients require individualized regimens ranging from every 2-4 weeks to remain symptom-free 4. Titrate based on symptom resolution, not serum B12 levels.
Monitoring pitfalls: Do not use serum B12 or MMA levels to "titrate" injection frequency during maintenance therapy 4. Clinical symptom resolution is the appropriate endpoint.
Alternative Routes (Context-Dependent)
While intramuscular therapy remains the gold standard for malabsorption-related B12 deficiency, recent evidence suggests:
- Oral supplementation: High-dose oral cyanocobalamin (1000 mcg daily) can be effective even in pernicious anemia through passive absorption 5, though this contradicts traditional teaching and should be reserved for patients who refuse or cannot tolerate injections
- Intranasal administration: 1000 mcg intranasal formulations show efficacy in elderly patients 6, but are not widely available
However, for documented B12 deficiency due to malabsorption (including post-bariatric surgery), intramuscular administration is strongly preferred and should be the default approach 7, 4.
Monitoring During Treatment
- Days 5-7: Check hematocrit and reticulocyte count daily until hematocrit normalizes
- First 48 hours: Monitor serum potassium closely in patients with pernicious anemia, as rapid cell production can cause hypokalemia 2
- Baseline: Obtain hematocrit, reticulocyte count, B12, folate, and iron levels before treatment 2
If reticulocyte counts do not increase or remain elevated appropriately, reevaluate the diagnosis and consider complicating factors such as concurrent iron or folate deficiency 2.